e-learning
resources
Virtual 2020
Pre-Congress Content
Real-world data and registries of thoracic oncology
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Osimertinib as a second-line treatment for EGFR-mutated non-small cell lung cancer: the experience of a Pulmonology department
D. Dantas Barreto Rodrigues (Braga, Portugal), C. Lacerda (Braga, Portugal), F. Aguiar (Braga, Portugal), M. Araújo (Braga, Portugal), D. Pimenta (Braga, Portugal), L. Ferreira (Braga, Portugal)
Source:
Virtual Congress 2020 – Real-world data and registries of thoracic oncology
Session:
Real-world data and registries of thoracic oncology
Session type:
E-poster session
Number:
1693
Disease area:
Thoracic oncology
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
D. Dantas Barreto Rodrigues (Braga, Portugal), C. Lacerda (Braga, Portugal), F. Aguiar (Braga, Portugal), M. Araújo (Braga, Portugal), D. Pimenta (Braga, Portugal), L. Ferreira (Braga, Portugal). Osimertinib as a second-line treatment for EGFR-mutated non-small cell lung cancer: the experience of a Pulmonology department. 1693
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
Adjuvant chemotherapy in stage Ib of non-small cell lung cancer (NSCLC)-experience of a pneumology department
Source: Annual Congress 2009 - Treatment of lung cancer
Year: 2009
Chemotherapy in advanced nonsmall cell lung cancer
Source: Eur Respir Mon; 2009: 44: 271–283
Year: 2009
First- and second-line therapy for advanced nonsmall cell lung cancer
Source: Eur Respir J 2009; 33: 915-930
Year: 2009
Our experience with crizotinib in the treatment of non-small cell lung cancer
Source: Virtual Congress 2020 – Prognostic and predictive factors: treatment of lung cancer
Year: 2020
Pemetrexed in maintenance therapy of 164 patients with advanced non-small-cell lung cancer (NSCLC)
Source: International Congress 2016 – Lung cancer: therapeutic modalities, re-staging, and follow-up
Year: 2016
Weekly administration of gemcitabine in outpatient clinic for the patients with recurrent non-small cell lung cancer after pulmonary resection
Source: Eur Respir J 2006; 28: Suppl. 50, 781s
Year: 2006
Treatment of advanced non-small cell lung cancer
Source: Annual Congress 2005 - PG2 - Lung cancer: non-small cell lung cancer treatment
Year: 2005
Clinical outcome of S-1 monotherapy in patients with advanced non-small cell lung cancer after treatment of pemetrexed
Source: Annual Congress 2013 –Systemic therapy of lung cancer and quality of life
Year: 2013
Chemotherapy with oral vinorelbine for geriatric patients with advanced non-small cell lung cancer – preliminary results
Source: Eur Respir J 2006; 28: Suppl. 50, 752s
Year: 2006
Surgical vs non-surgical treatment of early stage non-small cell lung cancer: here's the fight
Source: ERS webinar 2021: Surgical vs non-surgical treatment of early stage non-small cell lung cancer: here's the fight
Year: 2021
The role of palliative radiotherapy in locally advanced non small cell lung cancer
Source: Annual Congress 2007 - Therapy of lung cancer
Year: 2007
Vinorelbin and cisplatin in the treatment of advanced stage non-small cell lung cancer: Indian experience
Source: Annual Congress 2008 - Treatment of thoracic tumours
Year: 2008
Second-line medical treatment for nonsmall cell lung cancer: what the studies say
Source: Annual Congress 2010 - Lung cancer progress after first-line therapy: which treatment makes sense and which does not?
Year: 2010
Radiotherapy in the treatment of nonsmall cell lung cancer
Source: Eur Respir Mon; 2009: 44: 207–243
Year: 2009
Use of erlotinib in management of advanced non-small cell lung cancer (NSCLC): The Czech Republic experience with the treatment of a non-selected population of 1735 patients (pts)
Source: Annual Congress 2011 - Treatment of lung cancer
Year: 2011
Second-line therapy in elderly patients with advanced nonsmall cell lung cancer
Source: Eur Respir J 2014; 43: 240-249
Year: 2004
Is there a difference in response to first line chemotherapy related to age in patients with locally advanced or metastatic non-small lung cancer?
Source: Annual Congress 2013 –Systemic therapy of lung cancer and quality of life
Year: 2013
Lung function evaluation in gemcitabine and concurrent radiotherapy treatment in nonsmall cell lung cancer (NSCLC)
Source: Eur Respir J 2001; 18: Suppl. 33, 376s
Year: 2001
Results of surgical treatment in elderly patients with non-small cell lung cancer (NSCLC)
Source: Eur Respir J 2002; 20: Suppl. 38, 463s
Year: 2002
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept